ViroGates
Market Cap
ø105.8m
Last Updated
2019/09/20 22:15 UTC
Data Sources
Company Financials
Executive Summary
ViroGates A/S, a medical technology company, provides various products to measure soluble urokinase plasminogen activating receptor in blood.
Snowflake
Fundamentals
Flawless balance sheet and overvalued.
Risks
- ViroGates has significant price volatility in the past 3 months.
- ViroGates is not covered by any analysts.
Share Price & News
How has ViroGates's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
-5.7%
VIRO
0.3%
DK Medical Equipment
1.4%
DK Market
1 Year Return
-57.4%
VIRO
0.2%
DK Medical Equipment
7.0%
DK Market
VIRO underperformed the Medical Equipment industry which returned 1.5% over the past year.
VIRO underperformed the Market in Denmark which returned 7% over the past year.
Share holder returns
| VIRO | Industry | Market | |
|---|---|---|---|
| 7 Day | -5.7% | 0.3% | 1.4% |
| 30 Day | -6.7% | -4.5% | 0.3% |
| 90 Day | -22.1% | 4.0% | 2.9% |
| 1 Year | -57.4%-57.4% | 1.5%0.2% | 10.3%7.0% |
| 3 Year | n/a | 67.4%59.2% | 34.8%23.6% |
| 5 Year | n/a | 118.4%99.3% | 65.4%41.4% |
Price Volatility Vs. Market
How volatile is ViroGates's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
Imagine Owning ViroGates (CPH:VIRO) While The Price Tanked 55%3 months ago | Simply Wall St
Do Directors Own ViroGates A/S (CPH:VIRO) Shares?9 months ago | Simply Wall St
Is ViroGates A/S's (CPH:VIRO) Balance Sheet A Threat To Its Future?Valuation
Is ViroGates undervalued based on future cash flows and its price relative to the stock market?
2x
Price to Book (PB) ratio
Intrinsic Value Based on Future Cash Flows
Unable to calculate intrinsic value for ViroGates to establish if it is available at moderate discount.
Unable to calculate intrinsic value for ViroGates to establish if it is available at substantial discount.
Price Based on Earnings
ViroGates is loss making, we can't compare its value to the DK Medical Equipment industry average.
ViroGates is loss making, we can't compare the value of its earnings to the Denmark market.
Price Based on Expected Growth
Unable to calculate PEG ratio for ViroGates, we can't assess if its growth is good value.
Price Based on Value of Assets
ViroGates is good value based on assets compared to the DK Medical Equipment industry average.
Next Steps
Future Growth
How is ViroGates expected to perform in the next 1 to 3 years based on estimates from 0 analysts?
11.8%
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as ViroGates has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Next Steps
- Examine ViroGates's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- ViroGates competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Healthcare industry.
Past Performance
How has ViroGates performed over the past 5 years?
-37.1%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
ViroGates does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
Unable to compare ViroGates's 1-year earnings growth to the 5-year average as it is not currently profitable.
Unable to compare ViroGates's 1-year growth to the DK Medical Equipment industry average as it is not currently profitable.
Return on Equity
It is difficult to establish if ViroGates has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
Return on Assets
It is difficult to establish if ViroGates has efficiently used its assets last year compared to the DK Medical Equipment industry average (Return on Assets) as it is loss-making.
Return on Capital Employed
It is difficult to establish if ViroGates improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Next Steps
Financial Health
How is ViroGates's financial position?
Financial Position Analysis
ViroGates is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
ViroGates has no long term commitments.
Debt to Equity History and Analysis
ViroGates has no debt.
ViroGates currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Balance Sheet
Low level of unsold assets.
ViroGates has no debt, it does not need to be covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
ViroGates has sufficient cash runway for 2.4 years based on current free cash flow.
ViroGates has sufficient cash runway for 1.6 years if free cash flow continues to grow at historical rates of 51.8% each year.
Next Steps
Dividend
What is ViroGates's current dividend yield, its reliability and sustainability?
Dividend Yield and Payments Analysis
Unable to evaluate ViroGates's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate ViroGates's dividend against the top 25% market benchmark as the company has not reported any payouts.
Unable to perform a dividend volatility check as ViroGates has not reported any payouts.
Unable to verify if ViroGates's dividend has been increasing as the company has not reported any payouts.
Current Payout to Shareholders
Unable to calculate sustainability of dividends as ViroGates has not reported any payouts.
Future Payout to Shareholders
Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
Next Steps
Management
What is the CEO of ViroGates's salary, the management and board of directors tenure and is there insider trading?
10.8yrs
Average management tenure
CEO
Jakob Knudsen (51yo)
8.4yrs
Tenure
Mr. Jakob Knudsen has been Director at ExpreS2ion Biotech Holding AB (publ) since April 19, 2017. Mr. Knudsen has been the Chief Executive Officer at ViroGates A/S since April 2011. Mr. Knudsen serves as a ...
Management Age and Tenure
10.8yrs
Average Tenure
56yo
Average Age
The average tenure for the ViroGates management team is over 5 years, this suggests they are a seasoned and experienced team.
Board Age and Tenure
4.6yrs
Average Tenure
58yo
Average Age
The tenure for the ViroGates board of directors is about average.
Insider Trading
No 3 month open market individual insider trading information.
Ownership Breakdown
Management Team
Jakob Knudsen (51yo)
Chief Executive Officer
- Tenure: 8.4yrs
Jesper Eugen-Olsen (56yo)
Co-Founder & Chief Scientific Officer
- Tenure: 19.7yrs
Jørgen Thorball (57yo)
Co-Founder & Director
- Tenure: 18.7yrs
May Dyvelkov (59yo)
Chief Financial Officer
- Tenure: 10.8yrs
Thomas Krarup (56yo)
Vice President of Global Sales & Marketing
- Tenure: 1.5yrs
Board Members
Lars Krogsgaard (52yo)
Director
- Tenure: 3.4yrs
Jørgen Thorball (57yo)
Co-Founder & Director
- Tenure: 18.7yrs
Peter Aaby (75yo)
Scientific Advisor
- Tenure: 0yrs
Bernd Uder (62yo)
Non-Executive Director
- Tenure: 4.6yrs
Lars Kongsbak (58yo)
Chairman of the Board
- Tenure: 4.6yrs
Knut Borch-Johnsen
Scientific Advisor
- Tenure: 12.7yrs
Company Information
ViroGates A/S's company bio, employee growth, exchange listings and data sources
Key Information
- Name: ViroGates A/S
- Ticker: VIRO
- Exchange: CPSE
- Founded: 2000
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: ø105.808m
- Shares outstanding: 3.03m
- Website: https://www.virogates.com
Number of Employees
Location
- ViroGates A/S
- Blokken 45
- Birkerød
- Capital Region of Denmark
- 3460
- Denmark
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| VIRO | CPSE (OMX Nordic Exchange Copenhagen) | Yes | Share Capital | DK | DKK | Jun 2018 |
Biography
ViroGates A/S, a medical technology company, provides various products to measure soluble urokinase plasminogen activating receptor in blood. The company develops and markets suPARnostic, a blood test used ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/09/20 22:15 |
| End of Day Share Price | 2019/09/20 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.